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Abstract
Background/Aim:  The role of humoral immunity in hepatitis C virus (HCV) infection is poorly understood.
Nevertheless, there is increasing interest in characterizing the neutralizing antibodies in the serum of HCV-infected
patients. Focus reduction assays have been widely used to evaluate neutralizing antibody responses against a range of
non-cytopathic viruses. Based on the recent development of a HCV cell culture system using the genotype 2 JFH-1-strain,
we developed a focus reduction assay for HCV-neutralizing antibodies.
Methods: The focus reduction assay was based on a standard microneutralization assay in which immunostained foci on
tissue culture plates are counted. The neutralizing anti-HCV antibodies titers of purified serum immunoglobulin samples
from seventy-seven individuals were determined using a 50% focus reduction neutralization assay. Each titer was
determined as the log value of the reciprocal antibody dilution that reduced the number of viral foci by 50%. IgG
antibodies were first purified from each serum in order to avoid the facilitating effect of HDL on HCV entry.
Results: The assay's cut-off using an ELISA and RNA HCV-negative samples was found to be 1.25 log, corresponding to
a dilution of 1:18. The assay was compared with a commercial HCV ELISA and exhibited specificity and sensitivity values
of 100% and 96.5%, respectively, and good reproducibility (with intra-assay and inter-assay coefficients of variation of
6.7% and 12.6%, respectively). The assay did not show any cross-reactivity with anti-HIV, anti-HBs or heterophile
antibody-positive samples. The neutralizing antibodies titers were 2.13 log (1:134) for homologous samples from HCV
genotype 2 infected patients harboring the same genotype as JFH-1 and 1.93 log (1:85) for heterologous samples from
patients infected by genotypes other than type 2. These results confirm the presence of broadly cross-neutralizing
antibodies already reported using the HCV pseudoparticles system.
Conclusion: This study presents a simple, specific and reproducible cell culture-based assay for determination of HCV-
neutralizing antibodies in human sera. The assay should be an important tool for gauging the relationship between the
neutralizing antibodies response and viral load kinetics in acutely or chronically infected patients and for investigating the
possible eradication or prevention of HCV infection by neutralizing antibodies.
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Background
Hepatitis C virus (HCV, a member of the Flaviviridae fam-
ily) is an enveloped, positive-stranded RNA virus that
preferentially replicates in hepatocytes. At least 170 mil-
lion people worldwide are persistently infected with hep-
atitis C virus. Chronic HCV infection is associated with a
significant risk of progression to cirrhosis and hepatocel-
lular carcinoma [1]. Antiviral therapy with pegylated
alpha-interferon and ribavirin (the current best therapeu-
tic regimen) is only successful in about 50% of all treated
patients.
Better knowledge of the viral and host factors that deter-
mine HCV clearance or persistence during the acute stage
of infection is needed in order to improve antiviral ther-
apy and to develop efficient vaccines. Studies focusing on
innate and cellular immune responses have shown that a
sufficiently large HCV inoculum is able to evade, subvert
or circumvent the host's defences. At present, the chim-
panzee is the only reliable experimental animal model in
which the initial post-HCV infection events and the effi-
cacy of vaccine candidates can be evaluated [2]. It has
been shown that HCV-specific T-cell immunity is impor-
tant in the control of HCV infection [3,4]. Several studies
have indicated a role for humoral immunity in the acute
stage of HCV infection but this aspect remains poorly
characterized. The E1 and E2 glycoproteins are thought to
be the viral attachment proteins and thus the main targets
for HCV-neutralizing antibodies; identification of protec-
tive epitopes conserved across different strains of HCV is
therefore a major challenge in vaccine design. A number
of antibodies capable of blocking E2 binding to cells or
cell receptors have been described, [5-8] some of which
neutralize HCV entry in animal or cellular models [9,10].
Cell entry has been shown to involve several surface mol-
ecules (notably including the tetraspanin CD81 and the
SR-BI receptor [11,12]), although further studies are
needed to better understand how viral entry occurs and
how it might be neutralized. Detection of neutralizing
antibodies in human blood had been problematical until
an efficient and reliable cell culture system for HCV
became available. Hence, the development of an in vitro
neutralization assay for HCV could be extremely valuable
for characterizing the humoral immune response to HCV
and for evaluating the potential of passive and active
immunization against hepatitis C. Recent studies using an
in vitro neutralization assay system (based on infectious
retroviral pseudoparticles (HCVpp) bearing HCV enve-
lope glycoproteins) have confirmed that HCV-infected
patient sera can indeed neutralize infection [13,14]. How-
ever, it has also been shown that the neutralizing activity
of antibodies from HCV-infected patients is attenuated by
a factor present in human serum, identified as the high-
density lipoprotein (HDL) fraction [11,13,15]. HDL facil-
itation of HCVpp entry is a post-binding event [16], sug-
gesting that HDLs favour internalization of virions and
thus the latter's escape from neutralizing antibodies.
Recently, an HCV cell culture model (HCVcc) has been
developed [17-19], allowing the production of virus par-
ticles that can be efficiently propagated in cell culture.
Some preliminary neutralization assays have been carried
out by these authors. In this study, we describe how we set
up a standardized focus reduction neutralization assay
based on HCVcc.
Results
HCV focus reduction neutralization assay
Focus reduction assays have been widely used to evaluate
the neutralizing antibody responses to viruses that can
form foci in infected cells. Following the recent develop-
ment of the HCVcc model, the principle of the focus
reduction assay has been applied to HCV-neutralizing
antibodies detection. The JFH-1 HCV 2a viral strain was
grown on a Huh-7 human hepatoma cell line. After three
days of infection and cell permeabilization, detection of
the HCV foci was carried out using an inactivated HCV-
positive patient serum primary antibody and a peroxi-
dase-coupled, Fc-specific anti-human IgG-antibody. The
reaction was revealed with DAB peroxidase substrate. The
viral foci were thus stained brown, making them easy to
count (see Fig. 1a). It has been recently shown that the
neutralizing activity of HCV antibodies is attenuated by a
serum factor associated with the HDL fraction. Hence,
HDLs were able to facilitate HCVpp and HCVcc entry via
a mechanism which depended on the expression of the
scavenger receptor BI (SR-BI) and its selective lipid-uptake
function [11,15,16,20]. In view of the role of HDL in HCV
entry, immunoglobulins were purified from each serum
sample prior to determination of the neutralizing anti-
body titer (see Fig. 1b).
Assay specificity and precision
The specificity of the HCV neutralization assay was
assessed by testing 20 anti-HCV-ELISA-negative samples,
including five positive for hepatitis B virus surface anti-
bodies (anti-HBs) and five positive for heterophile anti-
bodies. All samples tested negative with two commercial
anti-HCV antibody detection assays (Axsym® HCV Version
3.0, Abbott, Wiesbaden, Germany; Vitros® Anti-HCV rea-
gent pack, Ortho-Clinical Diagnostic, High Wycombe,
United Kingdom) and HCV-RNA-negative with a qualita-
tive, commercial assay (Cobas Amplicor HCV test Version
2.0, Roche Diagnostics, Meylan, France).
These anti-HCV-negative samples were compared with 11
samples from patients chronically infected with HCV gen-
otype 2. The neutralization titers of anti-HCV-negative
serum samples are shown in Fig. 2., with a mean value of
1.083 ± 0.083 (corresponding to a dilution of 1:12). TheVirology Journal 2007, 4:35 http://www.virologyj.com/content/4/1/35
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assay's cut-off (determined as the mean value for negative
samples plus two standard deviations) corresponded to a
dilution of 1:18. The assay exhibited specificity and sensi-
bility values of 100% and 96.5%, respectively. The assay
did not show any cross-reactivity with anti-HIV, anti-HBs
or heterophile antibody-positive samples (data not
shown). Conversely, the chronically HCV genotype 2-pos-
itive samples displayed strong reactions, with a mean
value of 2.128 ± 0.365 (corresponding to a dilution of
1:134) (p < 0.001).
Inter-assay variability was determined by testing one HCV
genotype 2 sample in 10 consecutive experiments (n =
10), whereas intra-assay variability was evaluated by test-
ing the same sample 10 times (n = 10) in the same exper-
iment, whilst running the dilution series. The intra-assay
and inter-assay coefficients of variation (CV) of the log
neutralization titers were 6.7% and 12.6%, respectively.
Homologous and heterologous genotype reactivity
Fifty-seven HCV-positive antibodies samples were evalu-
ated using the HCV focus reduction neutralization assay.
The genotypes were distributed as follows; for types 1a,
1b, 2, 3, 4 and 5, we studied 11, 11, 11, 12, 10 and 2 sam-
ples, respectively. The mean values of the different geno-
types is shown in Fig. 3. and Table 1. The mean log
neutralization titers for genotypes 1a, 2 and 3 are very
similar (2.046 ± 0.671 for genotype 1a, 2.128 ± 0.365 for
genotype 2 and 2.148 ± 0.478 for genotype 3). The mean
average values are lower for genotype 1b (1.747 ± 0.462)
and genotype 4 (1.786 ± 0.236). Strikingly, very high het-
erologous titers were observed for five patients – three
infected with HCV genotype 1a and two infected with
HCV genotype 3 (see Fig. 3a). There were too few geno-
type 5 samples to compare with the other genotypes but
the corresponding results nevertheless indicate that the
neutralization assay is suitable for this genotype. The two
(a) Typical pictures of HCVcc-infected Huh-7 cells observed under a light microscope (×40), showing the absence (on the left)  and presence (on the right) of focus-forming units (FFU) Figure 1
(a) Typical pictures of HCVcc-infected Huh-7 cells observed under a light microscope (×40), showing the absence (on the 
right) and presence (on the left) of focus-forming units (FFU). (b) A sample-based neutralizing assay, showing the number of 
FFU in Huh-7 cells following serial dilutions of purified IgG from a HCV-positive serum sample. Neutralizing anti-HCV antibod-
ies titers were expressed as the highest log dilution of IgG producing a 50% reduction in plaque count, as compared with con-
trols in which the dose of virus was known.
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determined log neutralization values for genotype 5 were
1.753 and 1.764, respectively. These results confirm the
presence of broadly cross-neutralizing antibodies, as
already reported using the previous HCV pseudoparticle
system (HCVpp).
The distribution of the log neutralization titers across all
the HCV ELISA and RNA-positive samples as a function of
the HCV genotype is shown in Fig. 3b. More than 60% of
the neutralizing antibodies titers fell in the range from 1.7
to 2.69 log titers, corresponding to dilutions of 1:50 and
1:500, respectively. Overall, 3.5% of the samples dis-
played a titer greater than log 3.0 (1:1000) and, con-
versely, 3.5% displayed a titer below the cut-off value, i.e.
log 1.25 (1:10). Thus, of 57 HCV-infected patients, only
two did not test positive for neutralizing antibodies in this
assay (the titers were 0.960 and 0.932, respectively).
Discussion
The role of neutralizing antibodies during acute and
chronic viral infection remains an important question and
has generated controversial results. Initially, the presence
of neutralizing antibodies was shown to control the HCV
load and to contribute to viral eradication in patients
capable of clearing the infection [13]. In other studies, the
appearance of neutralizing antibodies was delayed and
restricted to IgG1 antibodies in patients who develop a
chronic infection [2,21]. The chimpanzee model has been
critical for the study of HCV transmission and host
immune responses; however, neutralizing antibodies
were not detected in some animals that resolved their
infection – suggesting a minimal role in viral clearance, as
also observed in human studies [14,15]. Experimentally
infected chimpanzees and naturally infected humans can
be re-infected with homologous and heterologous HCV
strains, suggesting that the humoral immunity that devel-
ops after spontaneous resolution of acute hepatitis C is
not sterilizing [22-24]. During chronic infection in
humans, the presence and/or production of neutralizing
antibodies do not suffice for curing the infection but
could regulate the spread of the virus. Thus, it can be pos-
tulated that during chronic infection, viral mutants can
continuously escape the renewed production of neutraliz-
ing antibodies.
Retroviral pseudoparticles have been used to develop a
very interesting tool for measuring neutralizing antibod-
ies in vitro [14]. The assay has demonstrated the presence
of HCV-neutralizing antibodies in human sera with rela-
tively high titers (>1:320) and broadly neutralizing activ-
ity against different HCV genotypes. However, this model
does not represent genuine HCV virions; in particular, the
budding of retroviral particles is thought to be very differ-
ent and may involve a variety of cellular pathways. Char-
acterization of infectious retroviral pseudotype particles
bearing HCV glycoproteins have been shown to be very
heterogeneous, and so it is possible that these pseudopar-
ticles may not be as relevant as the native HCV virions
[25].
The recent development of a cell culture model for HCV
enables the production of native HCV virions that can be
efficiently propagated in cell culture [17-19]. This cell cul-
ture system has allowed us to develop a neutralization
assay for evaluating the level and the proportion of HCV-
neutralizing antibodies in chronically infected HCV
patients. We analysed a number of parameters (such as
practicability, reproducibility and specificity) and tested
the effect of a range of variables (viral inoculum size, incu-
bation time, fixation and permeabilization methods,
blocking and revelation reagents) on these parameters
(data not shown). Overall, the neutralization assay
described in this study performs similarly to standardized
neutralization assays for many other viruses [26-28].
The assay relies on the ability of the specific JFH-1 geno-
type 2 viral strain to replicate and multiply on a Huh-7
human hepatoma cell line in a cell culture model, ena-
bling the rapid detection of viral foci after 72 hours of
infection. Moreover, no secondary foci were detectable at
this time point. Fixation with paraformaldehyde and per-
meabilization with Triton X-100 were chosen in order to
preserve antigenicity and prevent the cell monolayer from
detaching during washes. Development with DAB perox-
ide substrate made it easy to count specifically coloured
Neutralization of HCVcc JFH-1 in infected Huh-7 cells for  two distinct populations of samples, characterized by the  presence (HCV genotype 2) or absence (HCV-negative) of  anti-HCV antibodies Figure 2
Neutralization of HCVcc JFH-1 in infected Huh-7 cells for 
two distinct populations of samples, characterized by the 
presence (HCV genotype 2) or absence (HCV-negative) of 
anti-HCV antibodies.
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(a) Neutralization results for genotypes 1a, 1b, 2, 3 and 4 with respect to HCVcc JFH-1 in infected Huh-7 cells Figure 3
(a) Neutralization results for genotypes 1a, 1b, 2, 3 and 4 with respect to HCVcc JFH-1 in infected Huh-7 cells. (b) Distribu-
tion of the neutralization anti-HCV antibodies titers (independently of the genotype).
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viral foci. The viral inoculum size is an important param-
eter; it has to be low enough to enable good assay sensi-
tivity but high enough to produce a statistically significant
number of foci, i.e. allowing the reduction in the number
of foci (and thus the effect of neutralization) to be moni-
tored. Thus, 100 FFUs were used as the inoculum in this
neutralization assay.
In order to test different human samples, we had to take
into account the ability of HDL to facilitate HCVcc entry
via a mechanism which depends on expression of the
scavenger receptor BI [11,15,16,20]. Given HDL's role in
HCV entry, immunoglobulins were purified from each
serum sample prior to determination of the neutralizing
antibodies titer; this frees the assay of the risk of non-spe-
cific neutralization activity of the serum via the effects of
HDL, the complement system and/or serum amyloid A
protein (SAA) [29].
The HCV neutralization assay exhibited good reproduci-
bility, for both duplicate assays and independent tests. As
expected, the intra-assay coefficient of variation (CV) was
lower than the interassay CV. The test also showed good
specificity, since there was no interaction with anti-HIV,
anti-HBV or heterophile antibodies. Very low titers were
found with HCV ELISA and RNA-negative samples, and
the assay's cut-off was determined as the mean titer for
negative samples plus two standard deviations (1.25 log,
corresponding to a dilution of 1:18).
Given that only the JFH-1 strain of HCV genotype 2a was
available for the assay, we evaluated the neutralization
titer of sera from patients chronically infected with other
HCV genotypes, i.e. 1, 2, 3, 4 and 5. Most of these sera
were detected as positive by the neutralization assay,
except for two sera from HCV genotype 1-infected
patients. These two samples presented a high specific anti-
body ratio according to the ELISA but only very low inhi-
bition by neutralization assay (far below the cut-off, in
fact). We conclude that either the samples lacked neutral-
izing antibodies or that any such antibodies that were
present did not cross-neutralize with HCV genotype 2a.
The sensitivity was 100% – not only for genotype 2 (the
genotype of the strain used for the assay) but also for other
HCV genotypes (except genotype 1). HCV genotype 5
antibodies were also measured but there were too few
samples for accurate testing. Moreover, the positive sera
(96.5%) had comparable and significantly high titers
(1.99 ± 0.63), whatever the genotype. This finding sug-
gests that most neutralizing antibodies are cross-reactive.
Another possibility is that most of the patients had been
previously infected by a genotype 2 strain. However, this
is unlikely because few genotype 2 strains are circulating
in France [30]. As expected for a neutralization test, the
assay presented in the present study appeared to be very
specific (independently of the genotype) and usable in
most circumstances. For most viral infections, neutraliza-
tion assays such as that described in this study are used as
reference assays. Thus, we are confident that as other
HCVcc genotypes become available, these assays will
replace the pseudoparticle assay in the near future because
they are probably more relevant. Our assay is somewhat
time-consuming and could be simplified by using one
dilution to count the foci; however, this type of "short cut"
would make it difficult to extrapolate to the dilution neu-
tralizing 50% of the inoculum. Another approach would
consist in using recombinant HCV capable of expressing
reporter genes (such as luciferase) in order to use a single
dilution and obtain a quantitative result [31]. However,
further neutralization studies using other genotypes are
needed in order to complete our observations and to char-
Table 1: HCV JFH-1 neutralization assay
Genotype Nba M/Fb ratio Age (yr) HCV RNAc (log 
IU/mL)
Mean ± SDd Rangee
1a 11 7/4 43 ± 6 5.90 ± 0.6 2.046 ± 0.671 0.926 – 3.121
1b 11 5/6 48 ± 16 6.16 ± 0.5 1.747 ± 0.462 0.934 – 2.356
2 11 9/2 63 ± 12 5.50 ± 0.9 2.128 ± 0.365 1.486 – 2.742
3 12 8/4 40 ± 11 5.66 ± 0.6 2.148 ± 0.478 1.326 – 2.977
4 10 4/6 45 ± 11 6.07 ± 0.7 1.786 ± 0.236 1.453 – 2.152
5 2 1/1 66 ± 14 6.06 ± 0.6 1.755 ± 0.005 nd
all 57 34/23 48 ± 15 5.83 ± 0.7 1.970 ± 0.491 0.934 – 3.121
a Number of samples tested.
b F, female; M, male.
c HCV RNA measured using the Amplicor HCV Monitor assay, version 2.0 (Roche Diagnostics, Meylan, France) and expressed in log equivalents of 
IU/mL.
d Neutralizing anti-HCV antibodies titers expressed in log units; mean ± SD
e Range of neutralizing anti-HCV antibodies titers, expressed in log unitsVirology Journal 2007, 4:35 http://www.virologyj.com/content/4/1/35
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acterize the homologous and heterologous potencies of
polyclonal and monoclonal neutralizing antibodies.
Conclusion
A simple, specific and reproducible cell culture-based neu-
tralization assay was developed for the determination of
neutralizing anti-HCV antibodies in human sera. This test
should be an important tool for gauging the relationship
between the neutralizing response and viral load kinetics
in acutely and chronically infected patients.
Methods
Cell culture and HCV production
The Huh-7 human hepatoma cells [32] were grown in
Dulbecco's minimum essential medium (Invitrogen) sup-
plemented with 10% fetal bovine serum. All cell cultures
were maintained in 5% CO2 at 37°C.
The plasmid pJFH-1 containing the full-length cDNA of
the JFH-1 isolate (which belongs to subtype 2a (GenBank
accession no. AB047639)), was a gift from Dr Wakita
(Department of Microbiology, Tokyo Metropolitan Insti-
tute for Neuroscience, Tokyo, Japan) and has been
described previously [17]. To generate genomic HCV
RNA, the plasmid pJFH-1 was linearized at the 3' end of
the HCV cDNA and used as a template for in vitro tran-
scription, as described previously [33]. Viral stocks were
obtained by harvesting cell culture supernatants and freez-
ing them at -80°C. Virus titration was performed on Huh-
7 cells with 6-well microtiter plates (Corning, NY) 72
hours after incubation, by immunostaining the cells with
antibodies from a HCV-positive patient serum that had
previously been inactivated at 56°C (see the section on
the virus neutralization assay). The viral titer was deter-
mined in triplicate from the mean number of foci and
expressed as focus forming units/mL (FFU/mL).
Patients and clinical samples
Seventy-seven human serum samples were tested. Collec-
tion of the sera was approved by the local Ethics Commit-
tee and informed consent had been obtained from the
donors. Fifty-seven of these samples were obtained from
chronically infected HCV patients. The presence of HCV
antibodies was determined and confirmed using two
third-generation HCV EIA assays (Axsym® HCV Version
3.0, Abbott, Wiesbaden, Germany and Vitros® Anti-HCV
reagent pack, Ortho-Clinical Diagnostic, High Wycombe,
United Kingdom). HCV RNA was determined with a qual-
itative commercial assay (Cobas Amplicor HCV test Ver-
sion 2.0, Roche Diagnostics, Meylan, France) and HCV
genotyping was performed by direct sequencing, as
described elsewhere [34]. The genotypes were distributed
as follows: 11, 11, 11, 12, 10 and 2 samples of types 1a,
1b, 2, 3, 4 and 5, respectively. A set of 20 anti-HCV-nega-
tive serum samples was used to evaluate the assay's specif-
icity, including five serum samples with positive hepatitis
B virus surface antibody (anti-HBs) status and five sera
from Epstein-Barr virus-infected patients that had tested
positive for heterophile antibodies. All serum samples
had been stored at -80°C upon collection and had not
been thawed until the time of assay.
Serum immunoglobulins purification
Serum immunoglobulins G (IgG) fraction was purified
using protein G-Sepharose (GE Healthcare, Orsay,
France). 400 μL of heat-inactivated serum was mixed with
200 μL of protein G-Sepharose immunobeads for 30 min
at 25°C and then centrifuged for 1 min at 3800 g. The
supernatant was discarded and the immunobeads were
then washed 3 times with 400 μL of Immunopure IgG
binding buffer (Pierce, Rockford, USA). 400 μL Immu-
nopure IgG Elution buffer (Pierce, Rockford, USA) were
added to the immunobeads, which were mixed thor-
oughly and then centrifuged for 1 min at 5000 g. The
supernatant was pooled and neutralized with 40 μL Tris-
HCL 1 M pH 8.0. The IgG concentration was determined
using a Bradford assay (Bio-Rad Protein Assay, Bio-Rad,
Marnes-la-Coquette, France). Purified IgG was stored at -
80°C.
HCV focus reduction neutralization assay
The HCV focus reduction neutralization assay was per-
formed in 96-well microtiter plates. Serial dilutions of
purified IgG (10 μg) ranging from 1:10 to 1:1,280 were
established. Each dilution was tested twice. 25 μL of each
sample was mixed with 25 μL of virus (100 FFU) in 96-
well microtiter plates and incubated for 1 hour at 37°C,
5% CO2. A volume of 100 μL of Huh-7 cell suspension
(10,000 cells/well) in culture medium was added and
incubated for 5 hours at 37°C, 5% CO2. After 5 hours, the
supernatants were removed and 100 μL of culture
medium were added to the monolayers. After 72 hours,
the cells were fixed with paraformaldehyde and permeabi-
lized with 0.5% Triton X-100. Primary antibody (a HCV-
positive patient serum inactivated at 56°C) was diluted to
1:500 prior to use and then incubated for 1 h at room tem-
perature. A peroxidase-coupled, Fc-specific anti-human
IgG antibody (Sigma, Saint Quentin Fallavier, France)
diluted to 1:200 was dispensed onto the cell monolayer
and incubated for 30 min at room temperature. The reac-
tion was developed with DAB peroxidase substrate
(Sigma, Saint Quentin Fallavier, France) and stopped after
10 min of incubation with distilled water. The number of
HCV foci in each dilution was determined. Controls were
included in each assay (non-neutralized virus, purified
IgG from each patient at a 1:10 dilution). The dilution
that neutralized 50% of the virus was calculated by curvi-
linear regression analysis using XLSTAT 2006 software
(Addinsoft SARL, Paris, France) [35]. Each titer was deter-Virology Journal 2007, 4:35 http://www.virologyj.com/content/4/1/35
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mined as the log value of the reciprocal antibody dilution
that reduced the number of viral foci by 50%.
Statistical analysis
Titers were expressed as logarithmic values and means ±
standard deviation were calculated. Student's t-test was
used to compare data between groups. p values below
0.05 were considered to be significant.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
CFo, SC and GD conceived, designed and performed the
analysis. CFo, SD, EB, AS carried out the bioassay. SC and
CFr performed the statistical analysis. DC, CW and VT
have given final approval for the version to be published.
SC and GD wrote the paper.
All authors have read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the Programme Hospitalier de 
Recherche Clinique de Picardie (Appel d'Offres Local, 2006) and the 
Agence Nationale de la Recherche sur le SIDA (ANRS, 2006).
We are grateful to Agnès Baron and Véronique Descamps for their expert 
technical assistance.
References
1. Lauer GM, Walker BD: Hepatitis C virus infection.  N Engl J Med
2001, 345:41-52.
2. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Fein-
stone SM, Alter H, Rice CM, McKeating JA: Neutralizing antibody
response during acute and chronic hepatitis C virus infec-
tion.  Proc Natl Acad Sci USA 2004, 101:10149-10154.
3. Rollier C, Depla E, Drexhage JA, Verschoor EJ, Verstrepen BE, Fatmi
A, Brinster C, Fournillier A, Whelan JA, Whelan M, et al.: Control of
heterologous hepatitis C virus infection in chimpanzees is
associated with the quality of vaccine-induced peripheral
Thelper immune response.  J Virol 2004, 78:187-196.
4. Lechmann M, Liang TJ: Vaccine development for hepatitis C.
Semin Liver Dis 2000, 20:211-226.
5. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH:
Functional analysis of hepatitis C virus E2 glycoproteins and
virus-like particles reveals structural dissimilarities between
different forms of E2.  J Gen Virol 2001, 82:1877-1883.
6. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk
P, Higginbottom A, Levy S, McKeating JA: Characterization of hep-
atitis C virus E2 glycoprotein interaction with a putative cel-
lular receptor, CD81.  J Virol 1999, 73:6235-6244.
7. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P,
Abrignani S, Foung SK: Human monoclonal antibodies that
inhibit binding of hepatitis C virus E2 protein to CD81 and
recognize conserved conformational epitopes.  J Virol 2000,
74:10407-10416.
8. Allander T, Drakenberg K, Beyene A, Rosa D, Abrignani S, Houghton
M, Widell A, Grillner L, Persson MA: Recombinant human mon-
oclonal antibodies against different conformational epitopes
of the E2 envelope glycoprotein of hepatitis C virus that
inhibit its interaction with CD81.  J Gen Virol 2000, 81:2451-2459.
9. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Sha-
piro M, Purcell RH: Prevention of hepatitis C virus infection in
chimpanzees after antibody-mediated in vitro neutraliza-
tion.  Proc Natl Acad Sci USA 1994, 91:7792-7796.
10. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura
H: Neutralizing antibodies against hepatitis C virus and the
emergence of neutralization escape mutant viruses.  J Virol
1994, 68:1494-1500.
11. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlot-
sky JM, Lavillette D, Cosset FL: An interplay between hypervari-
able region 1 of the hepatitis C virus E2 glycoprotein, the
scavenger receptor BI, and high-density lipoprotein pro-
motes both enhancement of infection and protection against
neutralizing antibodies.  J Virol 2005, 79:8217-8229.
12. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R,
Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S: Binding of
hepatitis C virus to CD81.  Science 1998, 282:938-941.
13. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E,
Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL:
Human serum facilitates hepatitis C virus infection, and neu-
tralizing responses inversely correlate with viral replication
kinetics at the acute phase of hepatitis C virus infection.  J
Virol 2005, 79:6023-6034.
14. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder
WC, Emerson SU, Cosset FL, Purcell RH: In vitro assay for neu-
tralizing antibody to hepatitis C virus: evidence for broadly
conserved neutralization epitopes.  Proc Natl Acad Sci USA 2003,
100:14199-14204.
15. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson
SU, Cosset FL, Purcell RH, Bukh J: Evidence for cross-genotype
neutralization of hepatitis C virus pseudo-particles and
enhancement of infectivity by apolipoprotein C1.  Proc Natl
Acad Sci USA 2005, 102:4560-4565.
16. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-
Dac N: High density lipoproteins facilitate hepatitis C virus
entry through the scavenger receptor class B type I.  J Biol
Chem 2005, 280:7793-7799.
17. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z,
Murthy K, Habermann A, Krausslich HG, Mizokami M, et al.: Produc-
tion of infectious hepatitis C virus in tissue culture from a
cloned viral genome.  Nat Med 2005, 11:791-796.
18. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC,
Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Com-
plete replication of hepatitis C virus in cell culture.  Science
2005, 309:623-626.
19. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wie-
land SF, Uprichard SL, Wakita T, Chisari FV: Robust hepatitis C
virus infection in vitro.  Proc Natl Acad Sci USA 2005,
102:9294-9299.
20. Voisset C, de Beeck AO, Horellou P, Dreux M, Gustot T, Duverlie G,
Cosset FL, Vu-Dac N, Dubuisson J: High-density lipoproteins
reduce the neutralizing effect of hepatitis C virus (HCV)-
infected patient antibodies by promoting HCV entry.  J Gen
Virol 2006, 87:2577-2581.
21. Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton
RG, Roundtree S, Thomas DL, McKeating J, Cox A: Humoral
immune response in acute hepatitis C virus infection.  Clin
Infect Dis 2005, 41:667-675.
22. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G:
Immunity in hepatitis C infection.  J Infect Dis 1992,
165:438-443.
23. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell
RH, Cao A, Farci P: Hepatitis C virus in multiple episodes of
acute hepatitis in polytransfused thalassaemic children.  Lan-
cet 1994, 343:388-390.
24. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR,
Mushahwar IK, Desai SM, Miller RH, Ogata N, et al.: Lack of protec-
tive immunity against reinfection with hepatitis C virus.  Sci-
ence 1992, 258:135-140.
25. Flint M, Logvinoff C, Rice CM, McKeating JA: Characterization of
infectious retroviral pseudotype particles bearing hepatitis
C virus glycoproteins.  J Virol 2004, 78:6875-6882.
2 6 . E y a l  O ,  O l s h e v s k y  U ,  L u s t i g  S ,  P a r a n  N ,  H a l e v y  M ,  S c h n e i d e r  P ,
Zomber G, Fuchs P: Development of a tissue-culture-based
enzyme-immunoassay method for the quantitation of anti-
vaccinia-neutralizing antibodies in human sera.  J Virol Methods
2005, 130:15-21.
27. Wang S, Sakhatskyy P, Chou TH, Lu S: Assays for the assessment
of neutralizing antibody activities against Severe Acute Res-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2007, 4:35 http://www.virologyj.com/content/4/1/35
Page 9 of 9
(page number not for citation purposes)
piratory Syndrome (SARS) associated coronavirus (SCV).  J
Immunol Methods 2005, 301:21-30.
28. Zielinska E, Liu D, Wu HY, Quiroz J, Rappaport R, Yang DP: Devel-
opment of an improved microneutralization assay for respi-
ratory syncytial virus by automated plaque counting using
imaging analysis.  Virol J 2005, 2:84.
29. Parren PW, Burton DR: The antiviral activity of antibodies in
vitro and in vivo.  Adv Immunol 2001, 77:195-262.
30. Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fou-
chard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, et al.:
Changing of hepatitis C virus genotype patterns in France at
the beginning of the third millenium: The GEMHEP GenoCII
Study.  J Viral Hepat 2005, 12:405-413.
31. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Piet-
schmann T, Bartenschlager R: Characterization of the early
steps of hepatitis C virus infection by using luciferase
reporter viruses.  J Virol 2006, 80:5308-5320.
32. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: Growth of
human hepatoma cells lines with differentiated functions in
chemically defined medium.  Cancer Res 1982, 42:3858-3863.
33. Rouille Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E,
Belouzard S, McKeating J, Patel AH, Maertens G, et al.: Subcellular
localization of hepatitis C virus structural proteins in a cell
culture system that efficiently replicates the virus.  J Virol 2006,
80:2832-2841.
34. Castelain S, Khorsi H, Zawadzki P, Sueur JM, Capron JP, Eb F, Duver-
lie G: Direct blotting electrophoresis for sequencing and gen-
otyping hepatitis C virus.  J Virol Methods 1997, 65:237-243.
35. Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, Marovich MA,
Sun W, Porter KR, Burgess TH: An immunocytometric assay
based on dengue infection via DC-SIGN permits rapid meas-
urement of anti-dengue neutralizing antibodies.  J Virol Meth-
ods 2006, 134:74-85.